Skip to main content

3-year-old Durham startup chases Covid-19 treatment with $100M

The Durham company is committing $100 million to advance a combination therapy aimed at treating Covid-19 following positive results from a trial sponsored by the National Institutes of Health.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.